CIDP treatment focuses on reducing and slowing the immune processes damaging your peripheral nervous system. It includes corticosteroids, intravenous immunoglobulin, and plasma exchange ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Albert Fiori was diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy or CIDP, a rare autoimmune disease that affects his eye, one arm and one leg. But he is not letting that stop him from ...

Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, has announced a collaboration with biotechnology startup FcR Therapeutics to develop recombinant nanobodies ...

We are positioned for significant expansion in 2025 with the FDA decision on approval of our pre-filled syringe, global CIDP rollout ... transform the treatment of autoimmune diseases.

Efgartigimod shows success in myositis trials after prior approvals in gMG/CIDP. Both IV and subcutaneous ... argenx is also seeking approval in many other autoimmune disorders.

CIDP is a treatable condition that affects the peripheral nervous system. IVIG, plasma exchange, and corticosteroid therapy are the first-line treatment options, but a newer medication for adults ...

Efgartigimod is being evaluated in more than 15 severe autoimmune diseases (including MG, CIDP and ITP), exploring the significance of FcRn biology across neurology and rheumatology indications ...